Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia

Blood

Volumn 112, Issue 3, 2008, Pages 814-821

  Raghavan, Manoj ^a   Smith, Lan Lan ^a   Lillington, Debra M ^a   Chaplin, Tracy ^a   Kakkas, Ioannis ^a   Molloy, Gael ^a   Chelala, Claude ^a   Cazier, Jean Baptiste ^a,b   Cavenagh, James D ^c   Fitzgibbon, Jude ^a   Lister, T Andrew ^a   Young, Bryan D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLT3 LIGAND; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; RECURRENT DISEASE; UNIPARENTAL DISOMY; CELL CLONE; CHROMOSOME 13; CHROMOSOME 19; CHROMOSOME 4; GENETIC RECOMBINATION; GENETICS; GENOTYPE; HOMOZYGOTE; MIDDLE AGED; MUTATION;

ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 4; CLONE CELLS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENOTYPE; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; RECOMBINATION, GENETIC; RECURRENCE; UNIPARENTAL DISOMY;

EID: 50949113696     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132431     Document Type: Article

References (50)

1. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine; cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction. TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21:4496-4504.
2. Bradstock KF Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood. 2005;105:481-488.
3. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRCAML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311-2318.
4. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
5. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
6. Milligan DW, Wheatley K, Littlewood T Craig JI, Burnett AK. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRCAML-HR randomized trial. Blood. 2006;107: 4614-4622.
7. Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia. 1995; 9:972-976.
8. Garson OM, Hagemeijer A, Sakurai M, et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Gancer Genet Cytogenet. 1989;40:187-202.
9. Kern W, Haferlach T, Schnittger S, Ludwig WD, Hiddemann W, Schoch C. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia. 2002;16: 2084-2091.10. Lapillonne H, Renneville A, Auvrignon A, et al.
10. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24: 1507-1515.
11. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2005;20: 87-94.
12. Diverio D, Rossi V, Awisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP Multicenter "AIDA"Trial. Blood. 1998;92: 784-789.
13. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML
14. and 12 trials. Blood. 2001;98:1752-1759.
15. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis; minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398.
16. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65:9152-9154.
17. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65:375-378.
18. Gorletta TA, Gasparini P, D'Elios MM, Trubia M. Pelicci PG, Di Fiore PP. Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype. Genes Chromosomes Cancer. 2005;44:334-337.
19. Gupta M, Raghavan M, Gale RE, et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer. Prepublished on May 27, 2008, as DOI 10.1002/gcc.20573.
20. Schaffer LG, Tommerup N. ISCN 2005: an international system for human cytogenetic nomenclature. Basel Switzerland: S. Karger; 2005.
21. Wong KK, Tsang YT, Shen J, et al. Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SN P) array with whole genome amplified DNA. Nucleic Acids Res. 2004; 32:e69.
22. Matsuzaki H, Loi H, Dong S, et al. Parallel genotyping of over 10.000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res. 2004;14:414-425.
23. Liu WM, Di X, Yang G, et al. Algorithms for large-scale genotyping microarrays. Bioinformatics. 2003;19:2397-2403.
24. Kennedy GC, Matsuzaki H, Dong S, et al. Largescale genotyping of complex DNA. Nat Biotechnol. 2003;21:1233-1237.
25. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo/. Accessed October 4, 2007.
26. Bignell GR, Huang J, Greshock J, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res. 2004; 14:287-295.
27. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding GGAAT/enhancer binding protein-alpha (C/EBPalpha). in acute myeloid leukemia. Nat Genet. 2001;27: 263-270.
28. Snaddon J, Smith ML, Neat M, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 2003;37: 72-78.
29. Kiyoi H, Naoe T Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
30. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113:983-988.
31. Lindblad-Toh K, Tanenbaum DM, Daly MJ, et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000;18:1001-1005.
32. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
33. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-7239.
34. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106: 3658-3665.
35. Bacher U, Haferlach C, Kern W, Haferlach T Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood. 2008;111:2527-2537.
36. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK. Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007; 110:1262-1270.
37. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552-1559.
38. Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12:501-513.38. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating
39. mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor. PKC412. Blood. 2005;105:54-60.
40. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701. a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103:3669-3676.
41. Lin LI, Chen CY, Lin DT et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11:1372-1379.
42. Wouters BJ, Sanders MA, Lugthart S, et al. Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia. Leukemia. 2007;21:2382-2384.
43. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403-2407.
44. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19: 329-334.
45. de Nooij-van Dalen AG, van Buuren-
46. van Seggelen VH, Mulder A, et al. Isolation and molecular characterization of spontaneous mutants of lymphoblastoid cells with extended loss of heterozygosity. Mutat Res. 1997;374:51-62.
47. Bungaro S, Raghavan M, Dell'Oro MG, et al. Assessment of submicroscopic genetic lesions by single nucleotide polymorphism arrays in a child with acute myeloid leukemia and FLT3-internal tandem duplication. Haematologica. 2006;91: 998-1000.
48. Nyvold CG, Stentoft J, Braendstrup K, et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications. Leukemia. 2006;20:2051-2054.
49. Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, Orntoft TF Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis. 2007;28:38-48.
50. Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005:65:8597-8603.